ArticleAmerican heart journal plus : cardiology research and practice2026
Mechanisms of gut microbiota metabolite-mediated gut-heart Axis in heart failure: An integrative study based on network pharmacology.
Article in American heart journal plus : cardiology research and practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Heart failure (HF) is a prevalent terminal-stage cardiovascular disease worldwide. Recent years have seen growing research on the gut-heart axis, yet the role of gut microbiota-derived metabolites in HF pathogenesis remains insufficiently explored. Methods: This network pharmacology study screened overlapping targets of heart failure and gut metabolites via gutMGene, GeneCards and OMIM databases, then carried out PPI, enrichment, M-S-M-T network construction, as well as drug-likeness and toxicity prediction of metabolites. Results: We identified 47 candidate targets at the intersection of HF-related genes and gut metabolite-associated targets. PPI network analysis suggested that AKT1, TNF, TP53, IL6, and PPARG may represent key hub targets. Functional enrichment indicated potential associations with the NF-κB and PI3K-Akt signaling pathways. The M-S-M-T regulatory network results show that PPARG is the hub target with the most extensive connections. Drug-likeness and toxicity predictions suggested favorable in silico profiles for five metabolites, including 3-indolepropionic acid (IPA) and indole-3-lactic acid (ILA). Conclusion: This network pharmacology study screened core genes, metabolites and pathways associated with the gut-heart axis in heart failure, providing hypothetical support for subsequent experimental research on intervening heart failure via gut microbiota-derived metabolites.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.